Home › Cancro al fegato (carcinoma epatocellulare) › Illinois
Studi clinici su Cancro al fegato (carcinoma epatocellulare) nello stato di Illinois
20 studi su Cancro al fegato (carcinoma epatocellulare) cercano partecipanti presso sedi nello stato di Illinois.
Città nello stato di Illinois
Testo ufficiale dello studio (inglese)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #26, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT05176483Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Memorial Hospital, Shiloh
- Siteman Cancer Center - Shiloh, Shiloh
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07227012National Liver Cancer Screening Trial
- Northwestern University, Chicago
In reclutamentoFase 4
Età da 18 a 85 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06084234A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0107, Chicago
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07291076Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- OSF St. Francis Medical Center, Peoria
In reclutamentoFase 2
Età da 18 a 100 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07219459A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- City of Hope Chicago Cancer Center, Zion
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT06427941Defining the Ablative Dose for Y-90 TARE
- Northwestern University, Chicago
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT07586046Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- RUSH University Medical Center, Chicago
- University of Chicago, Chicago
In reclutamentoStudio osservazionale
Età 22 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT06486454Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Chicago
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06921785Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Lurie Children's Hospital-Chicago, Chicago
In reclutamentoFase 1/2
12 Months – 30 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04851119Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle at The Riverfront, Danville
- e altri 6
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT07166406A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT06330064Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle Cancer Center NCI Community Oncology Research Program, Urbana
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT05168163DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
- Rush University Medical Center, Chicago
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 lug 2026 · NCT07717437Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
- Northwestern University, Chicago
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 giu 2026 · NCT07042919A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 giu 2026 · NCT06600321Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
- Northwestern University, Chicago
- Northwestern Medicine Kishwaukee Hospital, DeKalb
- Northwestern Medicine Delnor Hospital, Geneva
- e altri 4
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 mag 2026 · NCT05620771Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- University of Chicago Medical Center, Chicago
- Methodist Medical Center of Illinois, Peoria
In reclutamentoFase 4
Età da 18 a 64 · Tutti i sessi · Aggiornato il 22 gen 2026 · NCT04373564SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774The Dragon PLC Trial (DRAGON-PLC)
- Rush University Medical Center, Chicago
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 mag 2025 · NCT06914648Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.